Document is current
Any future updates will be listed below
-
Authors
Wang, Zhihua
Zhang, Xi https://orcid.org/0000-0002-2411-9001
Lu, Shu https://orcid.org/0000-0003-4338-7164
Zhang, Chuankai
Ma, Zhe
Su, Rui
Li, Yuanfang
Sun, Ting
Li, Yutao
Hong, Mingyang
Deng, Xinyi
Rafiee Monjezi, Mohammad
Hristov, Michael
Steffens, Sabine https://orcid.org/0000-0002-6892-9751
Santovito, Donato https://orcid.org/0000-0003-1811-4746
Dornmair, Klaus https://orcid.org/0000-0003-0342-5373
Ley, Klaus
Weber, Christian
Mohanta, Sarajo K. https://orcid.org/0000-0001-6144-4092
Habenicht, Andreas J. R. https://orcid.org/0000-0003-2901-3027
Yin, Changjun https://orcid.org/0000-0002-1913-4477
- License Information
-
More Information
Article History
Received: 3 July 2022
Accepted: 18 January 2023
First Online: 23 February 2023
Competing interests
: S.K.M., A.J.R.H. and C.Y. declare competing interests. C.Y., S.K.M. and A.J.R.H. are owners of Easemedcontrol R&D & Co KG, Munich, Germany; C.Z., A.J.R.H. and C.Y. are inventors on a pending patent application related to the diagnostics and therapeutic usages of TCRs/B cell receptors to treat atherosclerosis. The remaining authors declare no competing interests.
